Data gathered: December 1
Data Bits
Data Bits | Value / Change | Benchmark | |
---|---|---|---|
Job Posts | 0% |
|
|
Sentiment | 100 2% |
|
|
Webpage traffic | 24,000 28.1% |
|
|
4chan Mentions | 0% |
|
|
Facebook Engagement | 36 80% |
|
|
Facebook followers | 11,833 -0% |
|
|
Stocktwits Mentions | 55 -33.7% |
|
|
Stocktwits Subscribers | 5,890 0.7% |
|
|
Twitter Followers | 8,551 0.1% |
|
|
Instagram Followers | 15,951 0% |
|
|
News Mentions | 0% |
|
|
Reddit Mentions | 0% |
|
In the news
Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg DosesNovember 29 - Yahoo |
|
Cybin to discuss efficacy data for CYB003 for major depressive disorderNovember 29 - Thefly.com |
|
Cybin reports positive Phase 2 data for depression drug, files Form D with SECNovember 29 - Seeking Alpha |
|
GH Research, Compass Pathways Among Top Psychedelic Movers Of TodayNovember 22 - Benzinga |
|
![]() |
Penny Stocks To Buy Today? 3 To Watch Before ThanksgivingNovember 21 - PennyStocks |
Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York CityNovember 19 - Yahoo |
About Cybin
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.

Price | $0.44 |
Target Price | Sign up |
Market Cap | $206M |
Dividend Yield | 0 |
Industry | Biotechnology |
Similar companies
Financial performance View All
Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | |
---|---|---|---|---|---|
Q3 '23 | 0 | 0 | 0 | -12M | -16M |
Q2 '23 | 0 | 0 | 0 | -12M | -14M |
Q1 '23 | 0 | 0 | 0 | -14M | -13M |
Q4 '22 | 0 | 0 | 0 | -11M | -13M |
Q3 '22 | 0 | 0 | 0 | -10M | -14M |